vs
ケマーズ（CC）とEncompass Health Corp（EHC）の財務データ比較。上の社名をクリックして会社を切り替えられます
Encompass Health Corpの直近四半期売上が大きい（$1.5B vs $1.3B、ケマーズの約1.2倍）。Encompass Health Corpの純利益率が高く（9.5% vs -3.5%、差は13.0%）。Encompass Health Corpの前年同期比売上増加率が高い（9.9% vs -2.1%）。Encompass Health Corpの直近四半期フリーキャッシュフローが多い（$116.7M vs $92.0M）。過去8四半期でEncompass Health Corpの売上複合成長率が高い（8.3% vs -1.2%）
ケマーズ社は米国の化学企業で、2015年7月にデュポンから分社化して設立され、本社は米国デラウェア州ウィルミントンに所在します。非粘着特性で知られる有名ブランド「テフロン」（ポリテトラフルオロエチレンPTFE）をはじめ、二酸化チタンや冷媒ガスなどを製造しています。
エンコンパスヘルスコーポレーション（旧Amcare、HealthSouth）は米国アラバマ州バーミンガムに本社を置く米国最大の入院リハビリサービス事業者で、39州とプエルトリコに173の入院リハビリ病院を展開し、脳卒中や神経疾患、心肺疾患、脳損傷から回復中の患者に専門的な治療とケアを提供している。
CC vs EHC — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.3B | $1.5B |
| 純利益 | $-47.0M | $146.1M |
| 粗利率 | 11.7% | — |
| 営業利益率 | — | 16.7% |
| 純利益率 | -3.5% | 9.5% |
| 売上前年比 | -2.1% | 9.9% |
| 純利益前年比 | -261.5% | 20.8% |
| EPS（希薄化後） | $-0.32 | $1.43 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.5B | $1.5B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.4B | $1.5B | ||
| Q4 24 | $1.4B | $1.4B | ||
| Q3 24 | $1.5B | $1.4B | ||
| Q2 24 | $1.6B | $1.3B | ||
| Q1 24 | $1.4B | $1.3B |
| Q4 25 | $-47.0M | $146.1M | ||
| Q3 25 | $46.0M | $126.5M | ||
| Q2 25 | $-380.0M | $142.1M | ||
| Q1 25 | $-5.0M | $151.5M | ||
| Q4 24 | $-13.0M | $120.9M | ||
| Q3 24 | $-32.0M | $108.2M | ||
| Q2 24 | $60.0M | $114.1M | ||
| Q1 24 | $54.0M | $112.5M |
| Q4 25 | 11.7% | — | ||
| Q3 25 | 15.6% | — | ||
| Q2 25 | 17.2% | — | ||
| Q1 25 | 17.3% | — | ||
| Q4 24 | 19.4% | — | ||
| Q3 24 | 19.0% | — | ||
| Q2 24 | 19.8% | — | ||
| Q1 24 | 20.9% | — |
| Q4 25 | — | 16.7% | ||
| Q3 25 | 2.5% | 14.9% | ||
| Q2 25 | -15.4% | 16.2% | ||
| Q1 25 | — | 16.4% | ||
| Q4 24 | -0.1% | 14.3% | ||
| Q3 24 | -2.1% | 13.6% | ||
| Q2 24 | 4.4% | 14.3% | ||
| Q1 24 | 5.1% | 13.6% |
| Q4 25 | -3.5% | 9.5% | ||
| Q3 25 | 3.1% | 8.6% | ||
| Q2 25 | -23.5% | 9.7% | ||
| Q1 25 | -0.4% | 10.4% | ||
| Q4 24 | -1.0% | 8.6% | ||
| Q3 24 | -2.1% | 8.0% | ||
| Q2 24 | 3.9% | 8.8% | ||
| Q1 24 | 4.0% | 8.5% |
| Q4 25 | $-0.32 | $1.43 | ||
| Q3 25 | $0.31 | $1.24 | ||
| Q2 25 | $-2.53 | $1.39 | ||
| Q1 25 | $-0.03 | $1.48 | ||
| Q4 24 | $-0.07 | $1.18 | ||
| Q3 24 | $-0.22 | $1.06 | ||
| Q2 24 | $0.39 | $1.12 | ||
| Q1 24 | $0.36 | $1.10 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $670.0M | $72.2M |
| 総負債低いほど良い | $4.1B | $2.4B |
| 株主資本純資産 | $250.0M | $2.4B |
| 総資産 | $7.4B | $7.1B |
| 負債/資本比率低いほどレバレッジが低い | 16.40× | 1.00× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $670.0M | $72.2M | ||
| Q3 25 | $613.0M | $48.7M | ||
| Q2 25 | $502.0M | $99.1M | ||
| Q1 25 | $464.0M | $95.8M | ||
| Q4 24 | $713.0M | $85.4M | ||
| Q3 24 | $596.0M | $147.8M | ||
| Q2 24 | $604.0M | $154.4M | ||
| Q1 24 | $746.0M | $134.4M |
| Q4 25 | $4.1B | $2.4B | ||
| Q3 25 | $4.1B | $2.4B | ||
| Q2 25 | $4.1B | $2.3B | ||
| Q1 25 | $4.1B | $2.3B | ||
| Q4 24 | $4.1B | $2.4B | ||
| Q3 24 | $4.0B | $2.3B | ||
| Q2 24 | $4.0B | $2.7B | ||
| Q1 24 | $4.0B | $2.7B |
| Q4 25 | $250.0M | $2.4B | ||
| Q3 25 | $274.0M | $2.4B | ||
| Q2 25 | $228.0M | $2.3B | ||
| Q1 25 | $566.0M | $2.2B | ||
| Q4 24 | $571.0M | $2.1B | ||
| Q3 24 | $643.0M | $2.0B | ||
| Q2 24 | $714.0M | $1.8B | ||
| Q1 24 | $753.0M | $1.7B |
| Q4 25 | $7.4B | $7.1B | ||
| Q3 25 | $7.5B | $6.9B | ||
| Q2 25 | $7.5B | $6.8B | ||
| Q1 25 | $7.4B | $6.6B | ||
| Q4 24 | $7.5B | $6.5B | ||
| Q3 24 | $7.5B | $6.5B | ||
| Q2 24 | $7.2B | $6.4B | ||
| Q1 24 | $8.0B | $6.2B |
| Q4 25 | 16.40× | 1.00× | ||
| Q3 25 | 14.96× | 1.01× | ||
| Q2 25 | 17.99× | 1.02× | ||
| Q1 25 | 7.18× | 1.08× | ||
| Q4 24 | 7.11× | 1.14× | ||
| Q3 24 | 6.20× | 1.20× | ||
| Q2 24 | 5.53× | 1.46× | ||
| Q1 24 | 5.27× | 1.54× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $137.0M | $346.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $92.0M | $116.7M |
| FCFマージンFCF / 売上 | 6.9% | 7.6% |
| 設備投資強度設備投資 / 売上 | 3.4% | 14.8% |
| キャッシュ転換率営業CF / 純利益 | — | 2.37× |
| 直近12ヶ月FCF直近4四半期 | $51.0M | $439.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $137.0M | $346.0M | ||
| Q3 25 | $146.0M | $270.8M | ||
| Q2 25 | $93.0M | $270.2M | ||
| Q1 25 | $-112.0M | $288.6M | ||
| Q4 24 | $138.0M | $278.8M | ||
| Q3 24 | $139.0M | $267.8M | ||
| Q2 24 | $-620.0M | $217.4M | ||
| Q1 24 | $-290.0M | $238.8M |
| Q4 25 | $92.0M | $116.7M | ||
| Q3 25 | $105.0M | $83.7M | ||
| Q2 25 | $50.0M | $113.3M | ||
| Q1 25 | $-196.0M | $125.5M | ||
| Q4 24 | $29.0M | $80.1M | ||
| Q3 24 | $63.0M | $120.3M | ||
| Q2 24 | $-693.0M | $60.5M | ||
| Q1 24 | $-392.0M | $99.4M |
| Q4 25 | 6.9% | 7.6% | ||
| Q3 25 | 7.0% | 5.7% | ||
| Q2 25 | 3.1% | 7.8% | ||
| Q1 25 | -14.3% | 8.6% | ||
| Q4 24 | 2.1% | 5.7% | ||
| Q3 24 | 4.2% | 8.9% | ||
| Q2 24 | -44.6% | 4.6% | ||
| Q1 24 | -28.8% | 7.6% |
| Q4 25 | 3.4% | 14.8% | ||
| Q3 25 | 2.7% | 12.7% | ||
| Q2 25 | 2.7% | 10.8% | ||
| Q1 25 | 6.1% | 11.2% | ||
| Q4 24 | 8.0% | 14.1% | ||
| Q3 24 | 5.0% | 10.9% | ||
| Q2 24 | 4.7% | 12.1% | ||
| Q1 24 | 7.5% | 10.6% |
| Q4 25 | — | 2.37× | ||
| Q3 25 | 3.17× | 2.14× | ||
| Q2 25 | — | 1.90× | ||
| Q1 25 | — | 1.90× | ||
| Q4 24 | — | 2.31× | ||
| Q3 24 | — | 2.48× | ||
| Q2 24 | -10.33× | 1.91× | ||
| Q1 24 | -5.37× | 2.12× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CC
| Titanium Technologies | $563.0M | 42% |
| Thermal And Specialized Solutions | $443.0M | 33% |
| Advanced Performance Materials | $312.0M | 23% |
| Other Non-Reportable Segment | $12.0M | 1% |
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
